Overview: Aspergillus Galactomannan Serum TestIntroduction: The Aspergillus Galactomannan Serum Test detects Aspergillus antigen in blood to diagnose invasive fungal infections, causing fever or lung issues. Following 2023 IDSA guidelines, it uses an immunoassay for high sensitivity, aiding in infectious disease screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in mycology for patients with suspected fungal infections.
Other Names: Galactomannan Serum Assay, Aspergillus Blood Antigen Test.
FDA Status: FDA-cleared diagnostic test, meeting mycology standards for diagnostic accuracy.
Historical Milestone: Galactomannan serum testing began in the 2000s with fungal research. Immunoassays improved in the 2010s, enhancing sensitivity for invasive aspergillosis.
Purpose: Diagnoses invasive fungal infections, guides antifungal treatment, and monitors Aspergillus antigens in patients with fever or lung issues.
Test Parameters: 1. Aspergillus Galactomannan
Pretest Condition: No fasting required. Collect serum or plasma at any time. Report symptoms like fever or lung issues, and list medications.
Specimen: 2-5 mL serum (SST) or 2-4 mL plasma (EDTA). Centrifuge within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document fever, lung issues, or history of fungal infections. Include current medications, especially antifungals or immunosuppressants.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for antifungal therapy.
Procedural Considerations: Uses an immunoassay to detect Aspergillus galactomannan. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Hemolysis or improper storage can affect results. Early infections may yield false negatives.
Clinical Significance: Positive galactomannan confirms invasive aspergillosis, prompting antifungal treatment. Negative results may require further testing.
Specialist Consultation: Consult an infectious disease specialist or pulmonologist for result interpretation.
Additional Supporting Tests: BAL galactomannan, fungal culture, or chest CT to confirm aspergillosis.
Test Limitations: False positives may occur with other fungi. Results require clinical correlation.
References: IDSA Fungal Guidelines, 2023; Clinical Infectious Diseases, Pappas PG, 2022.
